FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small busi ...